Harvard Bioscience (NASDAQ:HBIO) Stock Crosses Below Two Hundred Day Moving Average of $4.50

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.50 and traded as low as $4.15. Harvard Bioscience shares last traded at $4.44, with a volume of 192,772 shares.

Harvard Bioscience Stock Performance

The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.42. The business has a 50-day moving average price of $4.37 and a two-hundred day moving average price of $4.50.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings results on Thursday, March 7th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $28.15 million for the quarter, compared to analyst estimates of $27.80 million. Harvard Bioscience had a positive return on equity of 2.75% and a negative net margin of 3.04%. As a group, research analysts expect that Harvard Bioscience, Inc. will post 0.14 EPS for the current year.

Hedge Funds Weigh In On Harvard Bioscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Harvard Bioscience by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 2,102,571 shares of the medical instruments supplier’s stock worth $11,249,000 after buying an additional 38,169 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Harvard Bioscience by 32.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 40,274 shares of the medical instruments supplier’s stock valued at $215,000 after purchasing an additional 9,893 shares in the last quarter. Meros Investment Management LP boosted its stake in Harvard Bioscience by 1.6% during the 4th quarter. Meros Investment Management LP now owns 819,750 shares of the medical instruments supplier’s stock valued at $4,386,000 after purchasing an additional 12,633 shares in the last quarter. Barclays PLC boosted its stake in Harvard Bioscience by 676.6% during the 4th quarter. Barclays PLC now owns 55,798 shares of the medical instruments supplier’s stock valued at $299,000 after purchasing an additional 48,613 shares in the last quarter. Finally, Granahan Investment Management LLC boosted its stake in Harvard Bioscience by 6.2% during the 4th quarter. Granahan Investment Management LLC now owns 1,843,484 shares of the medical instruments supplier’s stock valued at $9,863,000 after purchasing an additional 107,912 shares in the last quarter. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.